Major indices finish lower amid GE earnings disappointment >>> READ MORE

3 Biotech Stocks Where Momentum is Alive and Well

Take a swing for the fences with these three rising stars

      View All  

Questcor Pharmaceuticals

Questcor-logoLike Regeneron, Questcor (QCOR) should benefit from the growth of an existing product, Acthar Gel. This one took a pause at the end of year on questions surrounding marketing practices – specifically improper payments to doctors.

Putting that aside for a moment, the value here is compelling. Analysts expect the company to grow profits in 2014 by 23%. At current prices, shares trade for only 8 times earnings.

What you ultimately have with Questcor are two very strong, opposing forces. Shorts will take questions about the marketing and claim fraud hoping to push shares lower. Longs will see further expansion of the company’s products and the low valuation. I’d bet on the momentum longs here.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC